Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

AI Briefing

• – Fractyl Health initiates first-in-human clinical trial of RJVA-001 for type 2 diabetes in the Netherlands.
• – Authorization marks first gene therapy candidate to enter clinical development for the disease.
• – Revita and Rejuva enter pivotal and first-in-human stages, respectively.